Cardiotoxicity
126
25
35
37
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.3%
8 terminated out of 126 trials
82.2%
-4.3% vs benchmark
9%
11 trials in Phase 3/4
14%
5 of 37 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 37 completed trials
Clinical Trials (126)
The CARDIOPROTECT Trial
The STOP-MED CTRCD Trial
ANTthracycline-induced Inflammation and OXidative Stress: 10-year Follow-up
Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.
In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
Novel On-body Evaluation of Cardiac Health for Oncology
Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer
A Study of Blood Pressure Control During Cancer Treatment
Global Cardio Oncology Registry
Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity
Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib